Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s Why

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped down prior to trading on Wednesday . The stock had previously closed at $11.95, but opened at $11.41. Telix Pharmaceuticals shares last traded at $11.3190, with a volume of 71,306 shares trading hands.

More Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and assigned a $22 price target, implying substantial upside from recent trading levels. The bullish view indicates confidence in Telix’s growth prospects and the strategic rationale for the ITM transaction. Tickerreport.com: Wedbush Reaffirms Outperform Rating
• Positive Sentiment: Telix agreed to acquire ITM in a transaction valued at up to $2.35 billion, including $1.65 billion payable upfront and as much as $700 million in contingent consideration tied to regulatory approval and sales targets. The deal could secure critical cancer-treatment isotope supply, expand Telix’s radiopharmaceutical reach and create a larger oncology platform. Inside Monkey: Telix to Buy ITM
• Positive Sentiment: RBC upgraded Telix from “hold” to “moderate buy,” providing additional support for the stock after the acquisition announcement. Tickerreport.com: RBC Upgrades Telix
• Neutral Sentiment: Telix’s research and development presentation and merger call highlighted its oncology pipeline and strategic plans, but investors will likely need further details on integration, funding and the transaction’s effect on future earnings. Seeking Alpha: Telix Research and Development Day
• Negative Sentiment: The market’s initial reaction was negative because the acquisition is large relative to Telix and is expected to involve significant share issuance. Investors are concerned about dilution, valuation, integration risk and the possibility that the transaction will pressure near-term returns, helping explain the recent share-price decline. RTT News: Telix Stock Drops Following ITM Deal

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TLX shares. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Tuesday, September 15th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Finally, Wedbush restated an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $20.50.

Telix Pharmaceuticals Stock Down 5.9%

The company’s 50-day moving average is $11.32 and its 200 day moving average is $10.41. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85.

Institutional Trading of Telix Pharmaceuticals

Large investors have recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $1,731,000. Private Advisor Group LLC raised its stake in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares during the period. XY Capital Ltd grew its stake in Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after purchasing an additional 58,739 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares in the last quarter. Finally, Lazard Asset Management LLC grew its position in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares in the last quarter.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.